Maha Ghazzi

Prior to MMS, she has worked at Pfizer, most recently as Executive Director/Development Team Leader. In this role, she was responsible for leading late stage development teams for several candidates in thrombosis (apixaban) and atherosclerosis (Biologics: HDL infusions). Dr. Ghazzi also provided cross functional leadership to develop an integrated strategy, communicate with senior management for endorsement, and ensure timely implementation of agreed plans. She worked closely with opinion leaders and experts in the field in order to ensure that the clinical development plan was optimized to meet regulatory and commercial needs. Additionally, she interacted with regulatory agencies (FDA, CHMP, and PMDA) for alignment on clinical and non-clinical development plans.

With MMS, Dr. Ghazzi supports sponsors with distinct leadership tasks and leads teams through management of special safety topics, execution of specialized task forces, and assists internal and external teams with data summarizations for submissions. She reviews clinical sections of submissions and other documents and serves in a leadership capacity for various summarization teams. Additionally, she provides training to the in-house staff on clinical data interpretations.

Dr. Maha Ghazzi earned her Doctor of Pharmacy at the University of Michigan College of Pharmacy in Ann Arbor, Mich.

Suggested For You

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today 

perspectives

January 20th, 2026

Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration 

perspectives

January 13th, 2026

Making Clinical Trial Technology Work in Practice

fact sheet

December 17th, 2025

Advance Psychedelic Drug Development With Proven Regulatory and Data Expertise

fact sheet

December 17th, 2025

Agile Medical Writing Staff Augmentation When You Need Expertise Not Headcount

fact sheet

December 17th, 2025

Biometrics Solutions Fact Sheet: End-to-End Data Expertise for Complex Clinical Trials

whitepaper

December 17th, 2025

Estimands: Opportunity or Risk for Drug Developers?

perspectives

December 16th, 2025

Inside Pharma and Biotech’s Shifting Landscape and the Direction Leaders Are Giving for 2026